Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL808799 | 0.80 | DGAT1 (0.74) | DGAT1ALDH1A1TET2ELANEKCNN4 | |
| SCHEMBL28433326 | 0.79 | DGAT1 (0.41) | DGAT1ALDH1A1TET2KCNN4EGLN1 | |
| SCHEMBL23091415 | 0.77 | DGAT1 (0.70) | DGAT1ALDH1A1ELANEKCNN4 | |
| Iodide SCHEMBL10533676 | 0.77 | DGAT1 (0.70) | DGAT1ALDH1A1ELANEKCNN4 | |
| Ammonia Solution, Strong SCHEMBL7639328 | 0.77 | DGAT1 (0.70) | DGAT1ALDH1A1ELANEKCNN4 | |
| SCHEMBL6554740 | 0.75 | DGAT1 (0.48) | DGAT1ALDH1A1TET2ELANEKCNN4 | |
| SCHEMBL12100928 | 0.75 | DGAT1 (0.48) | DGAT1ALDH1A1ELANEKCNN4 | |
| SCHEMBL17040242 | 0.75 | ALDH1A1 (0.44) | DGAT1ALDH1A1TET2 | |
| SCHEMBL678560 | 0.75 | ALDH1A1 (0.41) | DGAT1ALDH1A1TET2EGLN1 | |
| SCHEMBL5859056 | 0.75 | DGAT1 (0.59) | DGAT1ALDH1A1ELANEKCNN4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104812762-B | Substituted cyclic pyrimidin and triazine and their purposes | 拜耳药业股份公司 | 2018-01-16 | — | — | CN | disclosed |
| EP-3107920-B1 | 3-(PYRIMIDINE-2-YL)IMIDAZO[1,2-A]PYRIDINES | Bayer Pharma AG (DE) | 2017-10-18 | — | — | EP | disclosed |
| EP-2802587-B1 | SUBSTITUTED, ANNELLATED IMIDAZOLES AND PYRAZOLES AND THEIR USE | BAYER IP GMBH (DE) | 2017-09-06 | — | — | EP | disclosed |
| EP-2802587-B1 | SUBSTITUTED, ANNELLATED IMIDAZOLES AND PYRAZOLES AND THEIR USE | BAYER IP GMBH (DE) | 2017-09-06 | — | — | EP | disclosed |
| EP-2729476-B1 | HETEROARYL SUBSTITUTED PYRAZOLOPYRIDINES AND THEIR USE AS STIMULATORS OF SOLUBLE GUANYLATE CYCLASE | BAYER IP GMBH (DE) | 2017-08-23 | — | — | EP | disclosed |
| CN-106977530-A | Ring fusion pyrimidine and triazine and its be used for treat and/or prevention of cardiovascular disease purposes | 拜耳知识产权有限责任公司 | 2017-07-25 | — | — | CN | disclosed |
| CN-103649093-B | Substituted imidazopyridine and Imidazopyridazine and application thereof | 拜耳知识产权有限责任公司 | 2017-07-07 | — | — | CN | disclosed |
| US-9688699-B2 | 3-(pyrimidine-2-yl)imidazo[1,2-a]pyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-27 | — | — | US | disclosed |
| US-9688699-B2 | 3-(pyrimidine-2-yl)imidazo[1,2-a]pyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-27 | — | — | US | disclosed |
| US-9688699-B2 | 3-(pyrimidine-2-yl)imidazo[1,2-a]pyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-27 | — | — | US | disclosed |
| WO-2013104703-A1 | SUBSTITUTED ANNULATED PYRIMIDINES AND TRIAZINES, AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-07-18 | — | — | WO | disclosed |
| EP-2590979-A1 | RING-FUSED PYRIMIDINES AND TRIAZINES AND USE THEREOF FOR THE TREATMENT AND/OR PROPHYLAXIS OF CARDIOVASCULAR DISEASES | Bayer Intellectual Property GmbH (DE) | 2013-05-15 | — | — | EP | disclosed |
| CN-103097387-A | Ring-fused pyrimidines and triazines and use thereof for treating and/or preventing cardiovascular diseases | BAYER IP GMBH | 2013-05-08 | — | — | CN | disclosed |
| WO-2013004785-A1 | HETEROARYL-SUBSTITUTED PYRAZOLOPYRIDINES AND USE THEREOF AS SOLUBLE GUANYLATE CYCLASE STIMULATORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-01-10 | — | — | WO | disclosed |
| WO-2012152629-A1 | SUBSTITUTED IMIDAZOPYRIDINES AND IMIDAZOPYRIDAZINES AND THE USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012143510-A1 | FLUOROALKYL-SUBSTITUTED PYRAZOLOPYRIDINES AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-26 | — | — | WO | disclosed |
| WO-2012004258-A9 | RING-FUSED PYRIMIDINES AND TRIAZINES AND USE THEREOF FOR THE TREATMENT AND/OR PROPHYLAXIS OF CARDIOVASCULAR DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-07 | — | — | WO | disclosed |
| WO-2012004258-A9 | RING-FUSED PYRIMIDINES AND TRIAZINES AND USE THEREOF FOR THE TREATMENT AND/OR PROPHYLAXIS OF CARDIOVASCULAR DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-07 | — | — | WO | disclosed |
| WO-2012004258-A1 | RING-FUSED PYRIMIDINES AND TRIAZINES AND USE THEREOF FOR THE TREATMENT AND/OR PROPHYLAXIS OF CARDIOVASCULAR DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012004258-A1 | RING-FUSED PYRIMIDINES AND TRIAZINES AND USE THEREOF FOR THE TREATMENT AND/OR PROPHYLAXIS OF CARDIOVASCULAR DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-12 | — | — | WO | disclosed |